Simparica: Key Benefits
Simparica: Well tolerated in dogs
Safety information Age Can be used in dogs from 8 weeks of age Weight Can be used in dogs from 1.3kg of bodyweight Adverse Events None at a maximum dose of 4mg/kg Margin of Safety In one overdose laboratory study, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum exposure dose and convulsions at 5 times the maximum exposure dose. All dogs recovered without treatment. Breeds Simparica is well tolerated in Collies with a deficient multidrug-resistance-protine1 following single oral administration at 5 times the recommended dose. Concurrent medication Simparica may be used in combination with other routine veterinary medications, including milbemycin oxime, moxidectin and pyrantel pamoate (in these studies efficacy was not investigated).
The safety profile of Simparica was extensively studied in both laboratory and field studies, performed worldwide. These studies overall involved more than 3000 doses of Simparica administered to over 1500 dogs.
Voluntary full consumption within one minute3
- Simparica is a tasty, hard chewable tablet readily accepted by dogs
- Can be given with or without food1
- In European field studies Simparica was highly palatable with 93% of doses voluntarily consumed by client owned dogs within 1 minute of being offered
Simparica: The range
Bodyweight (kg) Tablet strength (mg sarolaner) Number of tablets to be administered 1.3 - 2.5 5 One > 2.5 - 5 10 One > 5 - 10 20 One > 10 - 20 40 One > 20 - 40 80 One > 40 Appropriate combination of tables